- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDG-PET predicts response to chemo in Hodgkin's disease
FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.
FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.
Dr. Andrea Gallamini and colleagues in Italy and Denmark enrolled 260 advanced Hodgkin's lymphoma patients scheduled to receive six cycles of chemotherapy. Patients underwent F-18 FDG-PET imaging before the first and after the second chemo cycle. Those with positive and negative FDG-PET results at the second chemo cycle recorded a two-year progression-free survival rate of 12.8% and 95%, respectively (J Clin Oncol 2007;25[24]:3746-3752).
The study shows that FDG-PET can be a useful prognostic tool that will help sort patients into appropriate management paths, researchers said.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
